Both are compound patents, and both patents were filed around the same time
This suggests that targeting circ-PSEN1 could protect retinal cells from the damaging effects of high glucose levels
At Reliable MD, our professional team can help you choose the best option based on your needs, medical history, and lifestyle
Currently, these follow-on patents provide patent protections until the end of 2041 (Figure 11)
Keep in mind that, of the two semaglutides, Wegovy is the only one FDA-approved for weight loss
CJC-1295 No DAC / Ipamorelin is a peptide combination studied in laboratory research for its coordinated modulation of growth hormone signaling through two distinct, complementary mechanisms